Articles

In this article, the results from 2 studies of Isa-KRd in newly diagnosed multiple myeloma (NDMM) are summarized, with the GMMG-CONCEPT trial focusing on high-risk NDMM and the IFM 2020-02 MIDAS study focusing on transplant-eligible NDMM. Read More ›

This article summarizes a post-hoc analysis of data from the MASTER study and the GRIFFIN study of patients with newly diagnosed multiple myeloma with high-risk cytogenetic abnormalities. Read More ›

This article summarizes results from an ad hoc survey conducted to evaluate nurses’ experiences with subcutaneous isatuximab administration via an on-body delivery system. Read More ›

Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX
In this ninth installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations for using NALIRIFOX or FOLFIRINOX when treating patients with pancreatic cancer. Read More ›

Oncology nurses are often the first to hear about patients’ therapy-induced side effects. Understanding these challenges can help maximize your patients’ quality of life and keep their treatment plan on schedule. Read More ›

“Neither my education in nursing school nor graduate school prepared me for neuro-oncology,” writes Marissa Panzer, DNP, AGPCNP, AOCNP, who shares her experiences navigating the oncology world as a nurse practitioner. Read More ›

As the days grow shorter and darker, it’s easy to fall prey to feelings of sadness and isolation, and although you cannot always avoid experiencing seasonal affective disorder, you can make lifestyle changes to manage it and prevent future episodes. Read More ›

Biomarker testing is crucial in guiding treatment choices by pinpointing individuals who stand to gain from specific regimens, ultimately enhancing patient results. Nevertheless, the application of guideline-endorsed biomarker testing for advanced non–small cell lung cancer patients varies. Read More ›

MCLA-129 is a Biclonics-based product that can be categorized as a common light chain/bispecific antibody used to target EGFR and c-MET while enhancing antibody-dependent cellular cytotoxicity. Read More ›

Prostate cancer ranks as the second most common cause of cancer-related deaths among men in the United States. Aggressive forms of this cancer are linked to mutations in homologous recombination repair genes. Read More ›

Page 5 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: